CN rng

NEWS

新闻中心

Innovation-driven biopharmaceutical R&D enterprisesdf

Check category
/
/
/
Fapon Biopharma and CMAB Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

Fapon Biopharma and CMAB Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2019-12-02 15:34
  • Views:

(Summary description)The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB.

Fapon Biopharma and CMAB Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

(Summary description)The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB.

  • Categories:News
  • Author:
  • Origin:
  • Time of issue:2019-12-02 15:34
  • Views:
Information

· The newly founded relationship will combine the research and development ingenuity of Fapon Biopharma with the state-of-art biologics manufacturing services offered by CMAB

· The first in class biologic was independently discovered and developed by Fapon Biopharma and shows significant promise for the treatment of cancers such as lung, stomach and colorectal cancer

· CMAB will provide a full range of development and manufacturing services for Fapon Biopharma's biologic drug project

(Dongguan, China, Dec 2, 2019) Shenzhen Fapon Biopharma Inc. ("Fapon Biopharma"), an innovative biopharmaceutical company and CMAB Biopharma (Suzhou) Inc. ("CMAB"), a pure-play, biologics contract manufacturing and development organization (CDMO) announced a comprehensive strategic agreement for the development and manufacturing of an undisclosed biologic drug project.

  

 

According to the agreement, Fapon Biopharma will avail of the fully integrated CMC process development and manufacturing platform, the European QP audited product quality system and the experienced regulatory team in dual IND filings in both China and the United States at CMAB.

Quote from Dr. Lisheng Lu, Chief Scientist of Fapon Biopharma

"Fapon Biotechnology is a leading supplier of raw materials and solutions for IVD reagent, which is well-known in the industry for its leading R&D technology and excellent product quality.

With in-depth understanding of the pharmaceutical industry and strong resource support, Fapon Biopharma was established in 2015. With innovation-driven R&D as the core, our positioning is to develop and produce high-quality innovative biopharmaceuticals to save patients' lives.

After communication and the on-site investigation, we found that Fapon Biopharma is highly consistent with CMAB. Meeting our core needs, CMAB has a deep understanding of biologic drugs, and can formulate a CMC strategy to help us control risks and ensure that the milestones of each stage can be quickly reached with high quality."

Quote from Dr. Yongzhong Wang, CEO of CMAB Biopharma

"We are very excited and proud to be able to closely participate in this meaningful biologic drug development project of Fapon Biopharma. The founding aspiration and goal of CMAB is to make our customers successful as quickly as possible. We are willing and confident to work with innovative biopharmaceutical companies such as Fapon Biopharma to overcome technical difficulties, reduce R&D costs, reach milestones quickly and of high quality, and create sustainable value for customers."

Scan the QR code to read on your phone

Previous: None
Next: None
Previous: None
Next: None

logo

Tel:0769-22898960

Fax:523808

E-mail:[email protected]

Address:No. 5, Hualien Road, Taiwan Hi-Tech Park, Songshan Lake, Dongguan City, Guangdong Province, China

Copyright©Shenzhen Fapon Biopharma Co., Ltd. 
ICP09191313